CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Menu
Begin main content
Home About What We Do Programs and Services CADTH Reimbursement Review triheptanoin
Back to Programs and Services

CADTH Reimbursement Review

triheptanoin

Last Updated: April 1, 2021
Result type: Reports
Project Number: SR0684-000
Product Line: Reimbursement Review

Generic Name: triheptanoin

Brand Name: Dojolvi

Manufacturer: Ultragenyx Canada Inc

Therapeutic Area: Long-chain fatty acid oxidation disorders

Indications: Dojolvi (triheptanoin) is indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD). ​

Manufacturer Requested Reimbursement Criteria1: Ultragenyx is requesting triheptanoin be reimbursed for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD)

Submission Type: Initial

NOC Status at Filing: Post NOC

Project Status: Received

Companion Diagnostics: No

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openFebruary 26, 2021
Call for patient/clinician input closedApril 23, 2021
Submission receivedMarch 31, 2021
Submission accepted-
Submit Feedback